Chemotherapy and bio-chemotherapy in patients with advanced melanoma: Combination therapy with a nitrosourea

Journal of Chemotherapy

Volumn 15, Issue 2, 2003, Pages 198-202

  Ridolfi, Ruggero ^a,f   Tanganelli, L ^b   Scelzi, E ^c   Manente, P ^c   Palmeri, S ^d   Ravaioli, A ^e   Fiammenghi, L ^e   Romanini, A ^b  

^a Ospedale Pierantoni   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c Ospedale Civile   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^f MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Advanced melanoma; Bio chemotherapy; Chemotherapy; Immunomodulation; Melanoma; Nitrosourea

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; NITROSOUREA DERIVATIVE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0038289181     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.2.198     Document Type: Article

References (23)

1. Wingo PA, Tong P, Bolden S. Cancer statistics. CA Cancer J Clin 1995; 45: 8-30.
2. La Vecchia C, Lucchini F, Negri E, et al. Recent declines in worldwide mortality from cutaneous melanoma in youth and middle age. Int J Cancer 1999; 81: 62-6.
3. Nathan FE, Mastrangelo MJ. Systemic therapy in melanoma. Sem Surg Oncol 1998; 14: 319-27.
4. Ho RC. Medical management of Stage IV malignant melanoma. Medical issues. Cancer 1995; 75 (2 suppl):735-41.
5. Green RJ, Schuchter LM. Systemic treatment of metastatic melanoma with chemotherapy. Hematol Oncol Clin North Am 1998; 12: 863-75.
6. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16: 1752-9.
7. Richards JM, Gale D, Mehta N, et al. Combination of chemotherapy with interleukin-2 and interferon alpha for the treatment of metastatic melanoma. J Clin Oncol 1999; 17: 651-7.
8. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in a combination with interleukin-2 and interferon alpha-2b. J Clin Oncol 1999; 17: 968-75.
9. Eton O, Legha S, Bedikian A, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J Clin Oncol 2002; 20: 2045-52.
10. Ridolfi R, Sileni VC, Guida M, et al on behalf of the Italian Melanoma Intergroup (IMI). Cisplatin, dacarbazine with or without subcutaneous interleukin-e and alpha interferon in advanced melanoma out-patients: results from an Italian multicentric Phase III randomized clinical trial. J Clin Oncol 2002; 20: 1600-7.
11. Khayat D, Coeffic D, Antoine EC. Overview of the medical treatments of metastatic malignant melanoma. ASCO Educational Book 2000: 414-27.
12. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66: 1873-8.
13. Garcia ED, Santolaya, Requena T. Treatment of malignant melanoma. Ann Pharmacother 1999; 33: 730-8.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
15. Legha SS, Ring S, Papadopulos N, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 10: 2024-9.
16. Rixe O, Borel D, Benhammouda A, et al. Fotemustine, dacarbazine, vindesine combination therapy in advanced malignant melanoma: a phase II study of 43 patients. Melanoma Res 1995; 5: 419-24.
17. Steffens T, Bajorin DF, Chapman PB, et al. A phase II trial high-dose cisplatinum and dacarbazine. Cancer 1991, 68: 1230-7.
18. Flaherty LE, Robinson W, Redman BG et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993; 71: 3520-5.
19. Atkins MB, O'Boyle KR, Sosman JA et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994; 12: 1553-60.
20. Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15: 2579-88.
21. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 7: 2105-16.
22. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-base analysis of 631 patients. J Clin Oncol 1998; 16: 2921-9.
23. Terheyden P, Becker JC, Kampgen E, Brocker EB. Sequential interferon-α2b, interleukin-2 and fotemustine for patients with metastatic melanoma. Melanoma Res 2000; 10: 475-82.